SCHEMBL1563352

SCHEMBL1563352

CC(=NNC(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.81
NPC1 O15118 9/20 0.81
SMN1; SMN2 Q16637 8/20 0.81
KMT2A Q03164 6/20 0.81
MEN1 O00255 5/20 0.81
CYP1A2 P05177 1/20 0.81
CYP3A4 P08684 1/20 0.81
NFKB1 P19838 1/20 0.81
CYP2C19 P33261 1/20 0.81
CASP3 P42574 1/20 0.81
NFKB2 Q00653 1/20 0.81
RELA Q04206 1/20 0.81
SENP7 Q9BQF6 1/20 0.81
SENP6 Q9GZR1 1/20 0.81
MAPT P10636 7/20 0.75
POLB P06746 2/20 0.75
CA1 P00915 1/20 0.71
CA2 P00918 1/20 0.71
CA4 P22748 1/20 0.71
CA9 Q16790 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1563351 1.00 RAB9A (0.81) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL5732784 1.00 RAB9A (0.81) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL27532371 0.98 RAB9A (0.78) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL27178213 0.91 SMN1; SMN2 (0.74) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL27178172 0.91 MAPT (0.83) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL13576535 0.91 ALDH1A1 (0.78) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL27177918 0.91 ALDH1A1 (0.78) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL27177840 0.91 NPC1 (0.74) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL27177911 0.91 ALDH1A1 (0.78) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL27178219 0.91 SMN1; SMN2 (0.74) RAB9ANPC1SMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4580403-A2 APYRASE INHIBITORS Texas Crop Science, Inc. (US) 2025-07-09 EP claimed
US-20240101510-A1 APYRASE INHIBITORS TEXAS CROP SCIENCE, INC. 2024-03-28 US claimed
WO-2024050040-A2 APYRASE INHIBITORS TEXAS CROP SCIENCE (US) 2024-03-07 WO claimed
EP-0912467-B1 ASYMMETRIC HYDROGENATION METHOD OF A KETONIC COMPOUND AND DERIVATIVE RHODIA CHIMIE SA (FR) 2002-04-24 EP claimed
EP-0912467-A1 ASYMMETRIC HYDROGENATION METHOD OF A KETONIC COMPOUND AND DERIVATIVE RHODIA CHIMIE (FR) 1999-05-06 EP claimed
WO-1998000375-A1 ASYMMETRIC HYDROGENATION METHOD OF A KETONIC COMPOUND AND DERIVATIVE RHODIA CHIMIE (FR) 1998-01-08 WO claimed
EP-3668877-B1 INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS ST EUROPEO DI ONCOLOGIA S R L (IT) 2024-05-01 EP disclosed
US-20240101510-A1 APYRASE INHIBITORS TEXAS CROP SCIENCE, INC. 2024-03-28 US disclosed
EP-3189059-B1 THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS ST EUROPEO DI ONCOLOGIA S R L (IT) 2023-02-22 EP disclosed
CN-109641918-B Imidazoles as inhibitors of histone demethylases 欧洲肿瘤研究所有限责任公司 2021-12-21 CN disclosed
US-20210186905-A1 ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST EPIAXIS THERAPEUTICS PTY LTD (AU) 2021-06-24 US disclosed
US-10980777-B2 Indole derivatives as histone demethylase inhibitors ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2021-04-20 US disclosed
EP-3458460-B1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS ST EUROPEO DI ONCOLOGIA S R L (IT) 2020-12-09 EP disclosed
WO-1998000375-A1 ASYMMETRIC HYDROGENATION METHOD OF A KETONIC COMPOUND AND DERIVATIVE RHODIA CHIMIE (FR) 1998-01-08 WO disclosed
EP-0631571-B1 PREPARATION OF OPTICALLY ACTIVE HYDRAZINES AND AMINES DU PONT (US) 1997-06-04 EP disclosed
US-5543571-A Preparation of optically active hydrazines and amines E. I. DU PONT DE NEMOURS AND COMPANY (US) 1996-08-06 US disclosed
US-5426223-A Hydrogenation of n-acyl hydrazones in presence of catalyst comprising complex pf transition metal bonded to phosphine ligands E. I. DU PONT DE NEMOURS AND COMPANY (US) 1995-06-20 US disclosed
EP-0631571-A1 PREPARATION OF OPTICALLY ACTIVE HYDRAZINES AND AMINES. DU PONT (US) 1995-01-04 EP disclosed
US-5250731-A Asymmetric hydrogenation of N-acylhydrazones to N-acylhydrazines in presence of chiral phospholane complex E. I. DU PONT DE NEMOURS AND COMPANY (US) 1993-10-05 US disclosed
WO-1993019040-A1 PREPARATION OF OPTICALLY ACTIVE HYDRAZINES AND AMINES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1993-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10980777-B2 Indole derivatives as histone demethylase inhibitors KDM1B, KDM1A, INMT RAB9A 3283/4885NPC1 3639/4885SMN1; SMN2 3947/4885
US-20240101510-A1 APYRASE INHIBITORS APEH, DPEP1, PON1 RAB9A 1387/4885NPC1 2564/4885SMN1; SMN2 4511/4885
US-20210186905-A1 ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST PDCD1, CD274, PDCD1LG2 RAB9A 3538/4885NPC1 3375/4885SMN1; SMN2 2352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.